X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2223) 2223
Publication (335) 335
Book Review (29) 29
Book / eBook (9) 9
Book Chapter (8) 8
Magazine Article (8) 8
Conference Proceeding (5) 5
Newsletter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1436) 1436
male (1117) 1117
animals (945) 945
index medicus (936) 936
dronabinol - pharmacology (876) 876
dronabinol - therapeutic use (719) 719
female (689) 689
pharmacology & pharmacy (683) 683
adult (535) 535
cannabis (508) 508
cannabinoids (481) 481
marijuana (477) 477
neurosciences (472) 472
dronabinol - analogs & derivatives (455) 455
rats (426) 426
dose-response relationship, drug (366) 366
mice (359) 359
tetrahydrocannabinol (352) 352
dronabinol - administration & dosage (351) 351
middle aged (337) 337
psychiatry (332) 332
dronabinol (318) 318
dronabinol - adverse effects (291) 291
delta-9-tetrahydrocannabinol (272) 272
thc (257) 257
double-blind method (255) 255
cannabidiol (219) 219
clinical neurology (216) 216
article (212) 212
delta-tetrahydrocannabinol (206) 206
time factors (206) 206
cannabinoids - pharmacology (203) 203
cannabinoid (186) 186
cannabinoids - therapeutic use (180) 180
adolescent (177) 177
young adult (171) 171
drug combinations (161) 161
treatment outcome (154) 154
aged (149) 149
analysis (143) 143
rats, sprague-dawley (142) 142
dronabinol - blood (138) 138
brain (136) 136
pyrazoles - pharmacology (134) 134
pain (129) 129
piperidines - pharmacology (129) 129
pharmacology (127) 127
endocannabinoids (125) 125
mental disorders (124) 124
endocannabinoid system (123) 123
brain - drug effects (119) 119
dronabinol - metabolism (117) 117
disease models, animal (115) 115
drug interactions (113) 113
pain - drug therapy (112) 112
behavior, animal - drug effects (111) 111
receptor, cannabinoid, cb1 - metabolism (111) 111
antiemetics - therapeutic use (110) 110
administration, oral (109) 109
multiple sclerosis (109) 109
pharmacology/toxicology (108) 108
double-blind (107) 107
dronabinol - analysis (107) 107
multiple sclerosis - drug therapy (105) 105
muscle spasticity - drug therapy (105) 105
care and treatment (103) 103
clinical trials as topic (103) 103
plant extracts - therapeutic use (103) 103
biomedicine (101) 101
cannabidiol - therapeutic use (101) 101
cannabis - chemistry (101) 101
drugs (100) 100
research (100) 100
antineoplastic agents - adverse effects (98) 98
cross-over studies (98) 98
receptor (98) 98
dronabinol - pharmacokinetics (96) 96
health aspects (94) 94
phytotherapy (94) 94
motor activity - drug effects (93) 93
receptor, cannabinoid, cb1 - agonists (92) 92
spasticity (91) 91
dronabinol - toxicity (89) 89
anandamide (88) 88
mice, inbred c57bl (86) 86
vomiting - chemically induced (85) 85
psychomotor performance - drug effects (83) 83
drug abuse (82) 82
multiple-sclerosis (81) 81
nausea - drug therapy (81) 81
receptor, cannabinoid, cb1 - antagonists & inhibitors (81) 81
cannabidiol - pharmacology (80) 80
vomiting - drug therapy (80) 80
substance abuse (79) 79
dronabinol - chemistry (78) 78
medical marijuana (78) 78
heart rate - drug effects (75) 75
analgesics, non-narcotic - therapeutic use (74) 74
nausea - chemically induced (74) 74
brain - metabolism (72) 72
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2167) 2167
German (37) 37
French (19) 19
Spanish (7) 7
Japanese (4) 4
Polish (4) 4
Italian (3) 3
Norwegian (3) 3
Danish (2) 2
Russian (2) 2
Chinese (1) 1
Dutch (1) 1
Hebrew (1) 1
Hungarian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
REVISTA BRASILEIRA DE PSIQUIATRIA, ISSN 1516-4446, 05/2010, Volume 32, pp. S56 - S66
Journal Article
La Revue du praticien, ISSN 0035-2640, 02/2014, Volume 64, Issue 2, p. 165
The therapeutic use of cannabis has generated a lot of interest in the past years, leading to a better understanding of its mechanisms of action. Countries... 
Pain - drug therapy | Antiemetics - therapeutic use | Dronabinol - analogs & derivatives | Fibromyalgia - drug therapy | Humans | Cannabidiol | Plant Extracts - therapeutic use | Dronabinol - therapeutic use | Drug Combinations | Muscle Spasticity - drug therapy | Multiple Sclerosis - drug therapy
Journal Article
Philosophical Transactions: Biological Sciences, ISSN 0962-8436, 12/2012, Volume 367, Issue 1607, pp. 3353 - 3363
Human tissues express cannabinoid CB₁ and CB₂ receptors that can be activated by endogenously released 'endocannabinoids' or exogenously administered compounds... 
Receptors | Cannabinoids | Animal models | Pain | Medical treatment | Agonists | Morphine | Drug design | Endocannabinoids | Cannabinoid receptors | health and disease and epidemiology | Articles | And CB2 | Blood-brain barrier | Cannabinoid receptor agonists | Δ9-tetrahydrocannabinol | Cannabinoid CB1 | Therapeutic applications and strategies | blood-brain barrier | Delta-tetrahydrocannabinol | cannabinoid CB1 and CB2 receptors | CB2 RECEPTOR | LIVER-DISEASES | AMYOTROPHIC-LATERAL-SCLEROSIS | ANXIETY-LIKE BEHAVIOR | MU-OPIOID RECEPTOR | RAT FORMALIN TEST | therapeutic applications and strategies | cannabinoid receptor agonists | NEUROPATHIC PAIN | MOUSE MODEL | BIOLOGY | PENTYLENETETRAZOLE-INDUCED SEIZURE | CENTRAL-NERVOUS-SYSTEM | Endocannabinoids - metabolism | Analgesics - pharmacology | Receptor, Cannabinoid, CB2 - agonists | Cardiovascular Diseases - drug therapy | Humans | Cannabinoid Receptor Agonists - pharmacology | Neurodegenerative Diseases - drug therapy | Pain - metabolism | Receptor, Cannabinoid, CB1 - agonists | Pain - drug therapy | Cannabinoid Receptor Agonists - therapeutic use | Dronabinol - pharmacology | Analgesics - therapeutic use | Cardiovascular Diseases - metabolism | Risk Assessment | Analgesics - administration & dosage | Clinical Trials as Topic | Neurodegenerative Diseases - metabolism | Blood-Brain Barrier - drug effects | Cannabinoid Receptor Agonists - administration & dosage | Drug Discovery | Blood-Brain Barrier - metabolism | Receptor, Cannabinoid, CB1 - metabolism | Receptor, Cannabinoid, CB2 - metabolism | Animals | Dronabinol - therapeutic use | Review
Journal Article
Neurotherapeutics, ISSN 1933-7213, 2009, Volume 6, Issue 1, pp. 28 - 42
Traumatic brain injury (TBI) remains one of the leading causes of mortality and morbidity worldwide in individuals under the age of 45 years, and, despite... 
toll-like receptors | statins | minocycline | thyrotropin releasing hormone | progesterone | dexanabinol | bradykinin | cyclosporin | magnesium | substance P | Neurotrauma | erythropoietin | Neurosciences | Neurobiology | Neurosurgery | Neurology | Biomedicine | CONTROLLED CORTICAL IMPACT | FOCAL CEREBRAL-ISCHEMIA | RANDOMIZED CONTROLLED-TRIAL | NEUROSCIENCES | CLINICAL NEUROLOGY | EXCITATORY AMINO-ACIDS | MITOCHONDRIAL PERMEABILITY TRANSITION | CYCLOSPORINE-A | TRAUMATIC BRAIN-INJURY | PHARMACOLOGY & PHARMACY | SPINAL-CORD-INJURY | CENTRAL-NERVOUS-SYSTEM | Neuroprotective Agents - therapeutic use | Brain Injuries - drug therapy | Erythropoietin - therapeutic use | Humans | Oxidative Stress - physiology | Mitochondria - drug effects | Brain Injuries - physiopathology | Toll-Like Receptors - agonists | Magnesium - therapeutic use | Psychotropic Drugs - therapeutic use | Progesterone - therapeutic use | Cyclosporine - therapeutic use | Animals | Kinins - antagonists & inhibitors | Brain Edema - physiopathology | Minocycline - therapeutic use | Dronabinol - analogs & derivatives | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Thyrotropin-Releasing Hormone - therapeutic use | Brain Edema - drug therapy | Oxidative Stress - drug effects | Mitochondria - physiology | Dronabinol - therapeutic use | Brain | Progesterone | Erythropoietin | Injuries | Statins | Clinical trials | Review
Journal Article